Increasing Candida antifungal resistance in Eastern India (2019-2023): A notable rise in amphotericin B resistance

Document Type : Short Communication

Authors

1 Department of Microbiology Ramakrishna Mission Seva Pratisthan (Vivekananda Institute of Medical Sciences)

2 Statistician, Ramakrishna Mission Seva Pratisthan (Vivekananda Institute of Medican Sciences)

3 Department of General Medicine, Ramakrishna Mission Seva Pratisthan (Vivekananda Institute of Medical Sciences)

10.22034/cmm.2024.345262.1555

Abstract

Background and Purpose: This study analyzed the species diversity and antifungal drug sensitivity of Candida isolates reported from 2019 to 2023 at our hospital to guide empirical treatment protocols.
Materials and Methods: Clinical samples were cultured by standard microbiological techniques; subsequently, yeast isolates deemed clinically significant were identified and tested for antifungal drug sensitivity using the Vitek 2 Compact system (BioMerieux, France). Statistical analysis was performed in SPSS software and P-values of less than 0.05 were considered statistically significant.
Results: Diversity of species as well as the antifungal drug resistance of Candida isolates increased markedly over the period of 5 years. Moreover, a high percentage of isolates resistant to Amphotericin B and Voriconazole was noted.
Conclusion: These findings emphasized the need for caution in the empirical use of antifungal medications. Similar surveillance at regional levels is necessary and antifungal drug sensitivity should be included in hospital antibiograms to prevent the spread of multi-drug-resistant nosocomial strains.

Keywords

Main Subjects

References

  1. Badiee P, Hashemizadeh A. Opportunistic invasive fungal infections: diagnosis & clinical management. Indian J Med Res. 2014;139(2):195–204.
  2. Hirano R, Sakamoto Y, Kudo K, Ohnishi M. Retrospective analysis of mortality and Candida isolates of 75 patients with candidemia: a single hospital experience. Infect Drug Resist. 2015;8:199–205.
  3. Chakrabarti A, Mohan B, Shrivastava SK, Marak RS, Ghosh A, Ray P. Change in distribution & antifungal susceptibility of Candida species isolated from Candidaemia cases in a tertiary care centre during 1996-2000. Ind J Med Res. 2002;116:5-12.
  4. Ng KP, Saw TL, Na SL, Soo-Hoo TS. Systemic Candida infection in university hospital 1997-1999: the distribution of Candida biotypes and antifungal susceptibility patterns. Mycopathologia. 2001;149(3):141-6.
  5. Mnge P, Okeleye BI, Vasaikar SD, Apalata T. Species distribution and antifungal susceptibility patterns of Candida isolates from a public tertiary teaching hospital in the Eastern Cape Province, South Africa. Braz J Med Biol Res. 2017;50(6):e5797.
  6. Orasch C, Marchetti O, Garbino J, Schrenzel J, Zimmerli S, Mühlethaler K, et al. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective Candidaemia survey from the fungal infection network of Switzerland. Clin Microbiol Infect. 2014;20(7):698-705.
  7. Perea S, Patterson TF. Antifungal Resistance in Pathogenic Fungi. Clin Infect Dis. 2002;35
    (9):1073–80.
  8. Perlin DS. Echinocandin Resistance in Candida. Clin Infect Dis. 2015;61(6):S612–7.
  9. Chowdhary A, Sharma C, Meis JF. Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog. 2017;13(5):e1006290.
  10. Sanglard D. Emerging Threats in Antifungal-Resistant Fungal Pathogens. Front Med. 2016;3:11.
  11. Fournier P, Schwebel C, Maubon D, Vesin A, Lebeau B, Foroni L, et al. Antifungal use influences Candida species distribution and susceptibility in the intensive care unit. J Antimicrob Chemother. 2011;66(12):2880–6.
  12. Bassetti M, Ansaldi F, Nicolini L, Malfatto E, Molinari MP, Mussap M, et al. Incidence of Candidaemia and relationship with fluconazole use in an intensive care unit. J Antimicrob Chemother. 2009;64:625–9.
  13. Pfaller MA, Carvalhaes CG, DeVries S, Rhomberg PR, Castanheira M. Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections. Med Mycol. 2022;60(5):myac028.
  14. Pendleton KM, Huffnagle GB, Dickson RP. The significance of Candida in the human respiratory tract: our evolving understanding. Pathog Dis. 2017;75(3):ftx029.
  15. Mathur P, Hasan F, Singh PK, Malhotra R, Walia K, Chowdhary A. Five-year profile of Candidaemia at an Indian trauma centre: High rates of Candida auris blood stream infections. Mycoses. 2018;61(9):674-80.
  16. Rudramurthy SM, Chakrabarti A, Paul RA, Sood P, Kaur H, Capoor MR, et al. Candida auris Candidaemia in Indian ICUs: analysis of risk factors. J Antimicrob Chemother. 2017;72(6):1794-801.
  17. Chowdhary A, Tarai B, Singh A, Sharma A. Multidrug-Resistant Candida auris Infections in Critically Ill Coronavirus Disease Patients, India, April-July 2020. Emerg Infect Dis. 2020;26(11):2694-6.
  18. Bhattacharjee P. Epidemiology and antifungal susceptibility of Candida species in a tertiary care hospital, Kolkata, India. Curr Med Mycol. 2016;2(2):20-7.
  19. Thomas M, Oberoi A, Dewan E. Species distribution and antifungal susceptibility of candidemia at a multispecialty center in North India. CHRISMED J Health Res. 2016;3(1):33-6.
  20. Vaghela GM, Purohit LN, Kariya PV. Susceptibility of Candida species to antifungal drugs in Western India. Nat J Med Res. 2015;5(2):122-6.
  21. Pahwa N, Kumar R, Nirkhiwale S, Bandi A. Species distribution and drug susceptibility of Candida in clinical isolates from a tertiary care centre at Indore. Ind J Med Microbiol. 2014;
    32(1):44-8.
  22. Basu S, Gugnani HC, Joshi S, Gupta N. Distribution of Candida species in different clinical sources in Delhi, India, and proteinase and phospholipase activity of Candida albicans Rev Iberoam Micol. 2003;20(4):137-40.
  23. Dutta V, Lyngdoh WV, Bora I, Choudhury B, Khyriem AB, Bhattacharyya P. Characterization of Candida species from Intensive Care Unit Isolates in a Tertiary Care Centre in North-East India: A retrospective study. Int J Med Public Health. 2015;5(4):312-6.
  24. Kurup Rajgopal S. Prevalence and Antifungal Susceptibilities of Candida spp from a South Indian Tertiary Care Hospital. Int J Med Res and Rev. 2017;5(2):98-104.
  25. Giri S, Kindo AJ, Kalyani J. Candidemia in intensive care unit patients: A one year study from a tertiary care center in South India. J Post Grad Med. 2013;59(3):190-5.

 

Current Medical Mycology
Volume 10, Continuous
2024
Pages 1-5

Files

History

  • Receive Date: 06 July 2024
  • Revise Date: 29 September 2024
  • Accept Date: 26 October 2024
  • Publish Date: 15 November 2024

Share

How to cite

Statistics